June 9, 2021

FDA Approval of a New Treatment: What’s Next for the Alzheimer’s Community?

Thumbnail

FDA Approval of a New Treatment: What’s Next for the Alzheimer’s Community?

About This Episode

The Food and Drug Administration (FDA) has approved aducanumab as a new treatment for early-stage Alzheimer’s disease, and this AlzTalks explores what this means for the Alzheimer’s community.

Host Meryl Comer talked about the drug treatment with Biogen’s Samantha Budd Haeberlein, PhD, SVP, Head of Neurodegeneration Development and Karin Hellsvik, Head, External Communications and Patient Advocacy, and had a conversation about the decision with George Vradenburg, chairman and co-founder of UsAgainstAlzheimer’s; Russ Paulsen, UsA’s chief operating officer; and Jason Resendez, executive director of the UsAgainstAlzheimer’s Center for Brain Health Equity. 

Meryl Comer also spoke about this new drug with advocates Jim and Geri Taylor. Geri, who lives with Alzheimer’s disease, participated in the clinical trial for this therapy.

Press the 'Play' button under the image at left to hear a podcast of the conversation, or watch the full session HERE.

BrainStorm Feed

84

Greg O'Brien – Advocating for Scientific Research for Alzheimer’s

Journalist and author Greg O'Brien, diagnosed with early-onset Alzheimer's over a decade ago, shares with BrainStorm host Meryl his determination t

LISTEN NOW
83

Doreen Monks – The Emotional Journey of Alzheimer’s and Dementia (part 2)

In this episode of BrainStorm, host Meryl Comer continues explore the challenges of dementia diagnosis in her interview with Doreen Monks, a former

LISTEN NOW
82

Doreen Monks – The Emotional Journey of Alzheimer’s and Dementia (part 1)

What if your life and career were upended with a diagnosis of Alzheimer’s only to learn eight years later that the diagnosis was wrong?  In th

LISTEN NOW